Program and Budget Update Rare Disease advisory Committee November 08 2022 Elizabeth Short Program specialist 2 3 4 5 MEDICAID EXPANSION September 2022 PARTICIPANTS 260132 EXPENDITURES ID: 998629
Download Presentation The PPT/PDF document "MO HealthNet PharmaCy" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. MO HealthNet PharmaCy Program and Budget UpdateRare Disease advisory Committee November 08, 2022Elizabeth Short, Program specialist
2. 2
3. 3
4. 4
5. 5MEDICAID EXPANSIONSeptember 2022PARTICIPANTS 260,132EXPENDITURES $26,015,090CLAIM COUNT 218,075
6. 6TOP 4 DRUG CLASSES PER FY FY2021 ExpendituresFY2021 Claim CountPaliperidone Palmitate(Invega)$50,783,64719,191Adalimumab(Humira)$47,631,9146,928Lurasidone HCL(Latuda)$40,962,69034,399Methylphenidate HCL(ADHD)$32,590,476121,636 FY2022 ExpendituresFY2022 Claim CountAdalimumab(Humira)$65,085,3088,983Paliperidone Palmitate(Invega)$55,188,35020,453Lurasidone HCL(Latuda)$43,154,24135,334Methylphenidate HCL(ADHD)$35,358,173130,708 FYTD2023 ExpendituresFYTD2023 Claim CountAdalimumab(Humira)$29,579,1813,807Paliperidone Palmitate(Invega)$20,676,4807,453Biktarvy(HIV)$17,384,6405,528Lurasidone HCL(Latuda)$15,640,21412,628
7. 7
8. 8
9. 9
10. 10Sept 2022 TOP TEN REIMBURSED DRUGS FOR CHILDREN 0-17
11. 11
12. 12